.Back to listing
Wed, Mar 19
Myriad Genetics’ Latest Attempt to Maintain Its Monopoly on Our Genes Rejected
Last June, the U.S. Supreme Court issued a unanimous ruling invalidating patents on human genes. The case was brought by the ACLU, along with the Public Patent Foundation, on behalf of 20medical organizations, geneticists, health advocacy groups, and patients and challenged patents controlled by Myriad Genetics on the BRCA1 and BRCA2 genes. Based on a 30-year-old U.S. Patent & Trademark Office policy, Myriad had obtained its patents on these two genes, which are closely associated with hereditary breast and ovarian cancer risk, and stopped other laboratories in the U.S. from providing genetic testing to patients, even when these labs wanted to offer different, more comprehensive, or less expensive tests. Read more.